Cerus


Company Update (NASDAQ:CERS): Cerus Corporation Announces First INTERCEPT Pathogen Reduced Platelet Units Produced in the Continental US

Cerus Corporation (NASDAQ:CERS) and the SunCoast Blood Bank announced that the first pathogen reduced platelet units have been produced in the continental US. This …

Stock Update (NASDAQ:CERS): Richard J. Benjamin, MD PhD Appointed as Cerus Corporation’s New Chief Medical Officer

Cerus Corporation (NASDAQ:CERS) announced that Richard J. Benjamin, MD PhD has been appointed as chief medical officer of Cerus, effective July 13, 2015.

Company Update (NASDAQ:CERS): Cerus Corporation to Present at AABB Symposium on Pathogen-Reduced Components

Cerus Corporation (NASDAQ:CERS) will be presenting at the AABB Symposium on Implementation of Pathogen-Reduced Blood Components taking place in Bethesda, Maryland from April …

MLV Maintains Buy On Cerus Following Phase II Results Of INTERCEPT Red Blood Cells

In a research report released today, MLV analyst George Zavoico reiterated a Buy rating on Cerus (NASDAQ:CERS) with a price target of $10, …

UPDATE: MLV Reiterates Bullish Stance On Cerus Following Two FDA Approvals In A Week

Just two days after approving Cerus’ (NASDAQ:CERS) INTERCEPT Blood System for Plasma, the FDA comes through and approves INTERCEPT Blood System for Platelets.  …

UPDATE: MLV Raises Cerus Price Target On The Back Of FDA Approval

MLV analyst George Zavoico is out again today with a new research note on Cerus (NASDAQ:CERS), raising his price target to $10 (from $7), while maintaining a …

MLV Reiterates Buy On Cerus Following FDA Approval For INTERCEPT

In a research report issued today, MLV analyst George Zavoico reiterated a Buy rating on Cerus Corp. (NASDAQ:CERS) with a $7 price target, as the company announced …

Cantor Maintains Buy On Cerus As Flurry Of News Are Expected

In a research report published this morning, Cantor analyst Caroline Corner maintained a Buy rating on Cerus (NASDAQ:CERS) with a $6.00 price target, …

MLV Reiterates Buy On Cerus As American Red Cross Decides To Use INTERCEPT Platelets In Puerto Rico

In a research note released today, MLV analyst George Zavoico reiterated a Buy rating on Cerus Corp. (NASDAQ:CERS) with a $6 price target, …

MLV Reiterates Buy On Cerus Following Submission Of Clinical Protocol To FDA For The Use Of INTERCEPT Plasma

In a research note published yesterday, MLV analyst George Zavoico reiterated a Buy rating on Cerus (NASDAQ:CERS) with a $6 price target, on …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts